Abbott Laboratories 8-K filings

Abbott Laboratories announced strong second-quarter 2026 financial results, with reported sales up 13.0% and comparable sales up 4.8%, while raising its full-year adjusted diluted EPS guidance.

Abbott Laboratories shareholders approved the 2026 Incentive Stock Program, replacing the 2017 program, and the board size was increased to thirteen directors.

Abbott Laboratories has reached a proposed settlement in a consolidated shareholder derivative lawsuit regarding infant formula manufacturing and oversight.

Abbott Laboratories reported Q1 2026 results and confirmed the completion of its acquisition of Exact Sciences, while providing updated full-year guidance.

Abbott Laboratories has finalized its acquisition of Exact Sciences, expanding its leadership in cancer screening and diagnostics.

Abbott Laboratories announced a $20 billion senior notes offering to finance its acquisition of Exact Sciences Corporation and for general corporate purposes.

Abbott announced robust fourth-quarter and full-year 2025 financial results, driven by strong Medical Devices and Established Pharmaceuticals growth, alongside an optimistic 2026 outlook.

Abbott Laboratories announced the appointment of Dr. Nita Ahuja to its Board of Directors and an increase in the board's size from twelve to thirteen members.

Abbott Laboratories has announced a temporary blackout period for its employee retirement plans due to administrative changes, restricting participant transactions.

Abbott announced a definitive agreement to acquire Exact Sciences for approximately $21 billion in cash, aiming to lead the fast-growing cancer diagnostics market.

Abbott Laboratories reported robust third-quarter sales growth, driven by its Medical Devices and Established Pharmaceuticals segments, while reaffirming its full-year financial outlook.

A leading healthcare company announced robust second-quarter 2025 financial results, driven by strong medical device sales and increased its full-year earnings and sales guidance.

Hubert L. Allen, Executive Vice President, General Counsel, and Secretary of Abbott Laboratories, has announced his plans to retire after a transition period.

Abbott Laboratories successfully held its Annual Meeting of Shareholders on April 25, 2025, electing its Board of Directors and ratifying Ernst & Young LLP as its auditors.

Abbott Laboratories announced positive first-quarter 2025 results, with sales growth and adjusted EPS exceeding expectations, and reaffirmed its full-year 2025 financial guidance.

Abbott announced robust fourth-quarter and full-year 2024 results, exceeding initial guidance and projecting strong growth for 2025.

Abbott Laboratories has extended the terms of its Change in Control Agreements with named executive officers through December 31, 2026.

Abbott's third-quarter results show strong sales growth, particularly in Medical Devices, leading to an increased full-year EPS guidance.

Abbott's second-quarter results show strong organic sales growth, particularly in Medical Devices, leading to an increase in full-year earnings guidance.

Robert E. Funck, Jr., Executive Vice President, Finance at Abbott Laboratories, will retire effective July 1, 2024, after 36 years of service.

Abbott Laboratories successfully held its annual shareholder meeting, electing the board of directors, ratifying the auditors, and approving executive compensation.

Abbott Laboratories reported strong first-quarter 2024 results, driven by double-digit organic growth in its base business, and subsequently raised its full-year sales and earnings per share guidance.

Abbott Laboratories has entered into a new $5 billion revolving credit agreement, replacing a previous agreement, to provide unsecured borrowing capacity.

Abbott's fourth-quarter sales increased by 1.5 percent, with a significant 11.0 percent organic growth excluding COVID-19 testing sales, while full-year sales decreased by 8.1 percent due to anticipated declines in COVID-19 testing-related sales.